We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+51.8%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$24.1M
Cap. Flow
-$43.1M
Cap. Flow %
-11.96%
Top 10 Hldgs %
41.39%
Holding
100
New
33
Increased
9
Reduced
32
Closed
23

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$11.1M
2
RNAM
Avidity Biosciences
RNAM
+$7.67M
3
CATX icon
Perspective Therapeutics
CATX
+$6.91M
4
SLDB icon
Solid Biosciences
SLDB
+$6.83M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$6.54M

Top Sells

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$13.7M
2
MGNX icon
MacroGenics
MGNX
+$11.8M
3
MDT icon
Medtronic
MDT
+$11.1M
4
SNY icon
Sanofi
SNY
+$10.9M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKTW icon
76
Rocket Pharmaceuticals Warrant
RCKTW
$149K
$31.4K 0.01%
104,828
– –
MRSN
77
CALL
DELISTED
Mersana Therapeutics
MRSN
$7.62K ﹤0.01%
68
-11,996
-99% -$1.19M
ALT icon
78
Altimmune
ALT
$552M
– –
-150,000
Closed -$1.69M
ANNX icon
79
Annexon
ANNX
$834M
– –
-417,429
Closed -$1.9M
APLS
80
DELISTED
Apellis Pharmaceuticals
APLS
– –
-10,000
Closed -$599K
ARGX icon
81
argenx
ARGX
$53.4B
– –
-4,826
Closed -$1.84M
BCRX icon
82
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-248,728
Closed -$1.49M
BHVN icon
83
Biohaven
BHVN
$2.03B
– –
-70,695
Closed -$3.03M
CRBU icon
84
Caribou Biosciences
CRBU
$145M
– –
-900,818
Closed -$5.16M
IMVT icon
85
Immunovant
IMVT
$7.93B
– –
-20,000
Closed -$843K
ISRG icon
86
Intuitive Surgical
ISRG
$127B
– –
-15,808
Closed -$5.33M
KALV
87
CALL
DELISTED
KalVista Pharmaceuticals
KALV
– –
-180,400
Closed -$2.21M
MDT icon
88
Medtronic
MDT
$109B
– –
-135,000
Closed -$11.1M
MLTX icon
89
MoonLake Immunotherapeutics
MLTX
$1.57B
– –
-50,000
Closed -$3.02M
NTLA icon
90
Intellia Therapeutics
NTLA
$1.49B
– –
-54,822
Closed -$1.67M
PEN icon
91
Penumbra
PEN
$12.7B
– –
-20,000
Closed -$5.03M
PMVP icon
92
PMV Pharmaceuticals
PMVP
$59.2M
– –
-550,000
Closed -$1.71M
SDGR icon
93
Schrodinger
SDGR
$1.13B
– –
-31,117
Closed -$1.11M
SLNO
94
DELISTED
Soleno Therapeutics
SLNO
– –
-73,665
Closed -$2.97M
SNY icon
95
Sanofi
SNY
$103B
– –
-220,000
Closed -$10.9M
SRPT icon
96
Sarepta Therapeutics
SRPT
$1.57B
– –
-46,884
Closed -$4.52M
UTHR icon
97
United Therapeutics
UTHR
$25.8B
– –
-16,360
Closed -$3.6M
VRDN icon
98
Viridian Therapeutics
VRDN
$2.09B
– –
-50,438
Closed -$1.1M
CBAY
99
DELISTED
Cymabay Therapeutics
CBAY
– –
-218,975
Closed -$5.17M
MRTX
100
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-150,000
Closed -$8.81M
1 2 3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Silverarc Capital Management held 100 positions worth $360M, up 7.2% from $336M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Silverarc Capital Management withdrew a net $43.1M in Q1 2024, closing 23 positions and reducing 32 holdings. Its most notable exit was Medtronic, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier.

Against the trend, Silverarc Capital Management opened a new position in C4 Therapeutics worth $11.7M.

  • Silverarc Capital Management's largest Q1 2024 buy was C4 Therapeutics: 1,435,931 shares worth $11.7M.
  • Silverarc Capital Management added most to Solid Biosciences in Q1 2024, an estimated $6.83M increase.
  • Silverarc Capital Management's biggest Q1 2024 reduction was Mersana Therapeutics, cutting an estimated $13.7M.
  • Silverarc Capital Management fully exited Medtronic in Q1 2024, selling an estimated $11.1M.
  • Silverarc Capital Management's ten largest holdings make up 41% of its $360M portfolio in Q1 2024.
  • Silverarc Capital Management opened 33 new positions and closed 23 in Q1 2024.
  • Silverarc Capital Management's portfolio value rose 7.2% quarter-over-quarter to $360M.

Based on Silverarc Capital Management's 13F filing for Q1 2024, filed 15 May 2024.